Fernand Labrie
Publications
Page 7 of 25, showing 50 records out of 1234 total, starting on record 301, ending on 350
| Publication | Category | Year |
|---|---|---|
| 934. Labrie, F. (1997) Flutamide plus castration in patients with previously untreated prostate cancer [Letter to the Editor re: Noldus et al. 47: 713-8, 1996]. Urology, 50: 479. | All publications | 1997 |
| 933. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Diamond, P., Lemay, M. (1997) Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen [Letter to the Editor: Reply to Brown and Feuer re 47: 212-7, 1996]. Urology, 49: 306-307. | All publications | 1997 |
| 932. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Bélanger, A., Candas, B. (1997) Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy of treatment in localized prostate cancer. Mol. Urol., 1: 253-261. | All publications | 1997 |
| 931. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y., Bélanger, A., Candas, B. (1997) Neoadjuvant hormonal therapy: the Canadian experience. Urology, 49: 56-64. | All publications | 1997 |
| 930. Labrie, F., Simard, J., Candas, B. (1997) Reply by the authors to: Editorial comment of: Comparison of in vitro effects of the pure antiandrogens OH-Flutamide, Casodex and Nilutamide on androgen-sensitive parameters [Reply to the authors/P.F. Schellhammer]. Urology, 49: 586-589. | All publications | 1997 |
| 929. Labrie, F., Simard, J., Singh, S.M., Candas, B. (1997) Estimated potency of Casodex: A problematic design [Letter to the Editor re Schellhammer et al. 45: 745-52, 1995]. Urology, 50: 309-313. | All publications | 1997 |
| 928. Laverdiere, J., Gomez, J.L., Cusan, L., Suburu, R.E., Diamond, P., Lemay, M., Candas, B., Fortin, A., Labrie, F. (1997) Beneficial effect of combination therapy administered prior to, during and following external beam radiation therapy in localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 37: 247-252. | All publications | 1997 |
| 927. Luo, S., Chen, C., Labrie, C., Candas, B., Singh, S.M., Labrie, F. (1997) Daily dosing with Flutamide or Casodex exerts maximal antiandrogenic activity. Urology, 50: 913-919. | All publications | 1997 |
| 926. Simard, J., Labrie, F. (1997) Recent advances in androgen receptor research: relative potencies of pure antiandrogens and implications for prostate cancer therapy, in: New diagnostic and treatment modalities in prostate cancer, Project in Knowledge, pp 15-23. | All publications | 1997 |
| 925. Simard, J., Singh, S.M., Labrie, F. (1997) Comparison of in vitro effects of the pure antiandrogens OH-Flutamide, Casodex and Nilutamide on androgen-sensitive parameters. Urology, 49: 580-589. | All publications | 1997 |
| 924. Durocher, F., Simard, J., Ouellette, J., Richard, V., Labrie, F., Pelletier, G. (1997) Localization of the BRCA1 gene expression in adult cynomolgus monkey tissues. J. Histochem. Cytochem., 45: 1173-1188. | All publications | 1997 |
| 923. Gauthier, S., Caron, B., Cloutier, J., Dory, Y.L., Favre, A., Larouche, D., Mailhot, J., Ouellet, C., Schwerdtfeger, A., Leblanc, G., Martel, C., Simard, J., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) (S)-(+)-[4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl]-2,2-dimethylpropanoate (EM-800): a highly potent, specific and orally active non-steroidal antiestrogen. J. Med. Chem., 40: 2117-2122. | All publications | 1997 |
| 922. Luo, S., Labrie, C., Bélanger, A., Labrie, F. (1997) Effect of dehydroepiandrosterone (DHEA) on bone mass, serum lipids, and dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Endocrinology, 138: 3387-3394. | All publications | 1997 |
| 921. Luo, S., Martel, C., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Long term inhibitory effects of a novel antiestrogen on the growth of ZR-75-1 and MCF-7 human breast cancer tumors in nude mice. Int. J. Cancer, 73: 735-739. | All publications | 1997 |
| 920. Luo, S., Martel, C., Sourla, A., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Comparative effects of 28-day treatment with the new antiestrogen EM-800 and tamoxifen on estrogen-sensitive parameters in the intact mouse. Int. J. Cancer, 73: 381-391. | All publications | 1997 |
| 919. Luo, S., Sourla, A., Labrie, C., Bélanger, A., Labrie, F. (1997) Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Endocrinology, 138: 4435-4444. | All publications | 1997 |
| 918. Luo, S., Stojanovic, M., Labrie, C., Labrie, F. (1997) Inhibitory effect of the novel antiestrogen EM-800 and medroxyprogesterone acetate (MPA) on estrone-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Int. J. Cancer, 73: 580-586. | All publications | 1997 |
| 917. Simard, J., Labrie, C., Bélanger, A., Gauthier, S., Singh, S.M., Mérand, Y., Labrie, F. (1997) Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int. J. Cancer, 73: 104-112. | All publications | 1997 |
| 916. Simard, J., Sanchez, R., Poirier, D., Gauthier, S., Singh, S.M., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Blockade of the stimulatory effect of estrogens, OH-Tamoxifen, OH-Toremifene, Droloxifene and Raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res., 57: 3494-3497. | All publications | 1997 |
| 915. Sourla, A., Luo, S., Labrie, C., Bélanger, A., Labrie, F. (1997) Morphological changes induced by six-month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800. Endocrinology, 138: 5605-5617. | All publications | 1997 |
| 914. Tremblay, G.B., Tremblay, A., Copeland, N.G., Gilbert, D.J., Jenkins, N.A., Labrie, F., Giguère, V. (1997) Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol. Endocrinol., 11: 353-365. | All publications | 1997 |
| 913. Labrie, F., Bélanger, A., Cusan, L., Candas, B. (1997) Physiological changes in DHEA are not reflected by the serum levels of active androgens and estrogens but of their metabolites: intracrinology. J. Clin. Endocrinol. Metab., 82: 2403-2409. | All publications | 1997 |
| 912. Labrie, F., Bélanger, A., Cusan, L., Gomez, J.L., Candas, B. (1997) Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J. Clin. Endocrinol. Metab., 82: 2396-2402. | All publications | 1997 |
| 911. Labrie, F., Diamond, P., Cusan, L., Gomez, J.L., Bélanger, A., Candas, B. (1997) Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J. Clin. Endocrinol. Metab., 82: 3498-3505. | All publications | 1997 |
| 910. Labrie, F., Luu-The, V., Lin, S.-X., Labrie, C., Simard, J., Breton, R., Bélanger, A. (1997) The key role of 17β-HSDs in sex steroid biology. Steroids, 62: 148-158. | All publications | 1997 |
| 909. Lourdusamy, M., Coté, J., Laplante, S., Labrie, F., Singh, S.M. (1997) Synthesis and in vitro Study of 17?-(N-Ureylne-N, N'-disubstituted)-4-methyl-4Aza-5?-androstan-3-ones as Selective Inhibitors of Type I 5??Reductase. Bioorg. Med. Chem., 5: 305-310. | All publications | 1997 |
| 908. Luu-The, V., Simard, J., Labrie, C., Bélanger, A., Labrie, F. (1997) Intracrinology and hormone-dependent cancers. Rev. Clin. Pharmacol., 11: 18-26. | All publications | 1997 |
| 907. Poulin, M.-J., Simard, J., Catford, J.-G., Labrie, F., Piché, Y. (1997) Response of symbiotic endomycorrhizal fungi to estrogens and antiestrogens. Mol. Plant. Microbe Interactions, 10: 481-487. | All publications | 1997 |
| 906. Tchernof, A., Labrie, F., Bélanger, A., Prud'Homme, D., Bouchard, C., Tremblay, A., Nadeau, A., Després, J.P. (1997) Relationships between endogenous steroid hormone, sex hormone-binding globulin and lipoprotein levels in men: contribution of visceral obesity, insulin levels and other metabolic variables. Atherosclerosis, 133: 235-244. | All publications | 1997 |
| 905. Tchernof, A., Labrie, F., Bélanger, A., Prud'Homme, D., Bouchard, C., Tremblay, A., Nadeau, A., Després, J.P. (1997) Androstane-3?, 17?-diol glucuronide as a steroid correlate of visceral obesity in men. J. Clin. Endocrinol. Metab., 82: 1528-1534. | All publications | 1997 |
| 904. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Bélanger, A., Candas, B. (1997). Combination therapy in localized prostate cancer (Chapter 4), in: Schrèoder, F.H., ed. Recent advances in prostate cancer and BPH: the Proceedings of the IV Congress on Progress and Controversies on Oncological Urology (PACIOu IV), held in Rotterdam, the Netherlands, April 1996, pp 31-43. | All publications | 1997 |
| 903. Labrie, F. (1997) Reply by the author to: Conflict of interest or widely held misconception. Urology, 50: 1028. | All publications | 1997 |
| 902. Labrie, F. (1997) Why the brain drain matters. The Globe and Mail, A25. | All publications | 1997 |
| 901. Azzi, A., Rehse, P.H., Zhu, D.-W., Campbell, R.L., Labrie, F., Lin, S.-X. (1996) Crystal structure of human estrogenic 17?-hydroxysteroid dehydrogenase complexed with 17?-estradiol. Nat. Struct. Biol., 3: 665-668. | All publications | 1996 |
| 900. Chen, C., Li, X., Singh, S.M., Bélanger, A., Labrie, F. (1996) Additive in vivo growth-inhibitory effects of Flutamide and Finasteride on androgen-sensitive Shionogi 115 carcinoma. Endocrine-Related Cancer, 3: 217-227. | All publications | 1996 |
| 899. Chen, C., Poulin, R., Labrie, F. (1996) Large Shionogi tumors lose their responsiveness to Flutamide treatment. J. Steroid Biochem. Mol. Biol., 58: 489-494. | All publications | 1996 |
| 898. Cusan, L., Gomez, J.L., Diamond, P., Candas, B., Labrie, F. (1996) Combined androgen blockade with GnRH analogues and Flutamide at all stages of prostate cancer (Chapter 15), in: Filicori, M. et Flamigni, C., eds: Treatment with GnRH Analogs: Controversies and Prospectives, New-York, The Parthenon Publishing Group, pp 125-137. | All publications | 1996 |
| 897. Dufort, I., Soucy, P., Labrie, F., Luu-The, V. (1996) Molecular cloning of human type 3 3alpha-hydroxysteroid dehydrogenase that differs from 20alpha-hydroxysteroid dehydrogenase by seven amino acids. Biochem. Biophys. Res. Commun., 228: 474-479. | All publications | 1996 |
| 896. Labrie, C., Flamand, M., Bélanger, A., Labrie, F. (1996) High bioavailability of DHEA administered percutaneously in the rat. J. Endocrinol., 150: S107-S118. | All publications | 1996 |
| 895. Labrie, F., Bélanger, A., Cusan, L., Labrie, C., Simard, J., Luu-The, V., Gomez, J.L., Diamond, P., Candas, B. (1996) History of LHRH agonist and combination therapy in prostate cancer. Endocrine-Related Cancer, 3: 243-278. | All publications | 1996 |
| 894. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Cusan, L., Gomez, J., Diamond, P., Candas, B. (1996) Sources d'androgènes chez l'homme et traitement hormonal du cancer de la prostate (Chapter 16), in: Belaisch, J., Drodowsky, M.A. et Vermeulen, A., eds: Progrès en Andrologie: Endocrinologie Masculine, Doin, pp 215-229. | All publications | 1996 |
| 893. Labrie, F., Candas, B., Cusan, L., Diamond, P., Gomez, J.L. (1996) Antiandrogen story erred [Letter to the Editor]. The Medical Post, 32: | All publications | 1996 |
| 892. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M. (1996) Diagnosis of advanced or non-curable prostate cancer can be practically eliminated by prostate-specific antigen. Urology, 47: 212-217. | All publications | 1996 |
| 891. Labrie, F., Cusan, L., Dupont, A., Gomez, J.-L., Simard, J., Luu-The, V., Pelletier, G., Labrie, C., Bélanger, A. (1996) Androgen receptor antagonists (Chapter 28), in: Adashi, E.Y., Rock, J.A. et Rosenwaks, Z., eds: Reproductive Endocrinology, Surgery and Technology, Philadelphia, Lippincott-Raven Publishers, pp 559-583. | All publications | 1996 |
| 890. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Bélanger, A., Candas, B. (1996) Combination therapy in localized prostate cancer (Chapter 4), in: Schroder, F.H., ed. Recent Advances in Prostate Cancer and BPH, Parthenon Publishing, pp 31-43. | All publications | 1996 |
| 889. Labrie, F., Dupont, A., Cusan, L., Gomez, J.L., Surubu, R., Diamond, P. (1996) Combination therapy with Flutamide: The therapy of choice from early to advanced stages of prostate cancer, in: Denis, L., ed. Antiandrogens in Prostatic Cancer, Italy, European School of Oncology, pp 63-74. | All publications | 1996 |
| 888. Labrie, F., Simard, J., Luu-The, V., Labrie, C., Bélanger, A. (1996) Adrenal androgens are responsible for 40-50% and not 5-10% of total prostatic androgens in 65-year-old men: intracrinology, in First International Consultation on Prostate Cancer, Monaco, pp Published on CD-ROM. | All publications | 1996 |
| 887. Luo, S., Martel, C., Leblanc, G., Candas, B., Singh, S.M., Labrie, C., Simard, J., Bélanger, A., Labrie, F. (1996) Relative potencies of flutamide and casodex: preclinical studies. Endocrine-Related Cancer, 3: 229-241. | All publications | 1996 |
| 886. Vaillancourt, L., Têtu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., Suburu, R.E., Diamond, P., Candas, B., Labrie, F. (1996). Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: a randomized study. Am. J. Surg. Pathol., 20: 86-93. | All publications | 1996 |
| 885. van der Kwast, T.H., Tetu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., Diamond, P., Labrie, F. (1996) Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Prostate, 28: 227-231. | All publications | 1996 |